May 2026 in “Journal of Medicinal Chemistry” This study introduces dAR-6–1, a novel PROTAC designed for the transdermal treatment of androgenetic alopecia (AGA), featuring a pyridazinyl glutarimide moiety for enhanced CRBN binding. The compound demonstrates potent androgen receptor (AR) degradation with a DC50 of 0.90 nM and Dmax of 91% in LNCaP cells, and a DC50 of 0.23 nM and Dmax of 90% in hDPC cells, alongside exceptional solubility (>500 mg·mL–1). Both in vitro and in vivo studies, including an AGA mouse model, confirmed its superior skin permeability and hair regeneration efficacy compared to minoxidil. These findings highlight dAR-6–1 as a promising candidate for AGA treatment and offer a strategic framework for developing transdermal PROTACs.
October 2024 in “Zagazig University Medical Journal” Transdermal delivery using a fractional CO2 laser is more effective for treating alopecia areata than injections.
91 citations
,
August 2024 in “Acta Pharmaceutica Sinica B” Microneedles can improve skin disease treatment by delivering drugs directly through the skin.
5 citations
,
August 2025 in “Drug Delivery and Translational Research” Lipid-polymer hybrid nanoparticles show promise for skin treatments but need better formulation strategies.
2 citations
,
August 2023 in “Pharmaceutics” New skin disease treatments using TDDS are improving but face challenges like side effects and high costs.